Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Siemens Healthineers AGSEMHF 78 EV-to-EBITDA is 9.67 as of Aug. 22, 2026, which is 29% below its 10-year median of 13.59. GuruFocus rates SEMHF with a GF Score™ of 78/100 and a GF Value™ of $58.36 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 516 Medical Devices & Instruments companies, Siemens Healthineers AG ranks better than 68.41% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Siemens Healthineers AG's enterprise value is $50,307 Mil.
Siemens Healthineers AG's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was $5,201 Mil. Therefore, Siemens Healthineers AG's EV-to-EBITDA for today is 9.67.
The historical rank and industry rank for Siemens Healthineers AG's EV-to-EBITDA or its related term are showing as below:
SEMHF'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 8.19 Med: 13.59 Max: 21.57
Current: 9.56
During the past 11 years, the highest EV-to-EBITDA of Siemens Healthineers AG was 21.57. The lowest was 8.19. And the median was 13.59.
SEMHF's EV-to-EBITDA is ranked better than 68.41% of 516
companies
in the Medical Devices & Instruments industry
Industry Median: 14.7
vs SEMHF: 9.56
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Siemens Healthineers AG (OTCPK:SEMHF) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Siemens Healthineers AG's PE Ratio (TTM) for today is calculated as:
Siemens Healthineers AG's share price for today is $47.59.
Siemens Healthineers AG's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $2.289.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Siemens Healthineers AG's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Siemens Healthineers AG EV-to-EBITDA vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Siemens Healthineers AG's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Siemens Healthineers AG's EV-to-EBITDA falls into.
Siemens Healthineers AG's current Enterprise Value is $50,307 Mil.
Siemens Healthineers AG's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $5,201 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Siemens Healthineers AG (SEMHF) has a EV-to-EBITDA of 9.67 as of Aug. 22, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Siemens Healthineers AG. This is 29% below median its historical median of 13.59. Over the past decade, Siemens Healthineers AG's EV-to-EBITDA has ranged from 8.19 to 21.57. According to the industry distribution chart, Siemens Healthineers AG ranks #163 out of 516 companies in the Medical Devices & Instruments industry, placing it in the top 31.6%.
Is Siemens Healthineers AG's EV-to-EBITDA too high?
Siemens Healthineers AG's current EV-to-EBITDA of 9.67 is 29% below median its 10-year median of 13.59. Over the past 10 years, this metric has ranged from a low of 8.19 to a high of 21.57. The Medical Devices & Instruments industry median EV-to-EBITDA is 14.70. Siemens Healthineers AG's value of 9.67 is 34.2% below this industry median. Based on the distribution chart, Siemens Healthineers AG ranks #163 out of 516 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Siemens Healthineers AG has a GF Score™ of 78/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Siemens Healthineers AG's EV-to-EBITDA compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Siemens Healthineers AG ranks #163 out of 516 companies for EV-to-EBITDA. This puts Siemens Healthineers AG in the upper half of its industry. The industry median EV-to-EBITDA is 14.70. Siemens Healthineers AG's value of 9.67 is 34.2% below this benchmark. Historically, Siemens Healthineers AG's own EV-to-EBITDA has ranged from 8.19 to 21.57 over the past decade. While the company's 10-year median is 13.59 vs. the industry median of 14.70, Siemens Healthineers AG has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Medical Devices & Instruments company?
The median EV-to-EBITDA among Medical Devices & Instruments companies is 14.70, based on 516 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Siemens Healthineers AG's current EV-to-EBITDA of 9.67 is 34.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Siemens Healthineers AG. For the Medical Devices & Instruments industry, the median EV-to-EBITDA is 14.70 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Siemens Healthineers AG's current EV-to-EBITDA is 9.67, which is 29% below median its own 10-year median of 13.59. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Siemens Healthineers AG stock overvalued right now?
Based on GuruFocus' analysis, Siemens Healthineers AG (SEMHF) is currently considered Modestly Undervalued. The stock's GF Value™ is $58.36, compared to a current price of $47.59 — trading 18.5% below its estimated fair value. The current EV-to-EBITDA is 9.67, which is 29% below median its 10-year median of 13.59 and 34.2% below the Medical Devices & Instruments industry median of 14.70. Siemens Healthineers AG's overall GF Score™ is 78/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Siemens Healthineers AG (SEMHF), the current EV-to-EBITDA is 9.67 as of Aug. 22, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Siemens Healthineers AG (SEMHF) Overvalued in 2026?
Based on GuruFocus' analysis, Siemens Healthineers AG stock appears to be undervalued.
The current stock price of $47.59 is trading 18.5% below its estimated GF Value™ of $58.36.
GuruFocus considers Siemens Healthineers AG to be Modestly Undervalued.
Key valuation signals for SEMHF:
EV-to-EBITDA: 9.67 (29% below median its 10-year median of 13.59)
GF Value™: $58.36 vs. price of $47.59 (18.5% below fair value)
Industry Position: 34.2% below the Medical Devices & Instruments median (#163 of 516)
No single metric tells the full story. See the SEMHF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Siemens Healthineers is engaged in therapeutic imaging, radiotherapy, laboratory, and point-of-care diagnostics. The imaging segment (56% of sales in fiscal 2025) includes magnetic resonance imaging, computed tomography, X-ray systems, molecular imaging, and ultrasound. The Varian segment (18% of sales) offers radiotherapy and other oncology solutions. The diagnostics segment (19%) includes in vitro diagnostics and point-of-care diagnostics. The advanced therapies (now part of precision therapy) segment (9%) products are designed to support image-guided minimally invasive treatments in cardiology, interventional radiology, and surgery. The Americas represents 44% of total sales, Europe, Middle East, and Africa 32%, and Asia-Pacific, including China (11%), the remainder.
78GF Score
Get the complete analysis for SEMHF
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SEMHF has been successfully added to your 
